Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2002 2
2003 2
2004 3
2005 5
2006 9
2007 24
2008 36
2009 99
2010 164
2011 298
2012 550
2013 643
2014 650
2015 663
2016 695
2017 733
2018 648
2019 551
2020 570
2021 549
2022 436
2023 340
2024 111

Text availability

Article attribute

Article type

Publication date

Search Results

6,879 results

Results by year

Filters applied: . Clear all
Page 1
Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism.
Paik J. Paik J. Paediatr Drugs. 2022 Jul;24(4):423-431. doi: 10.1007/s40272-022-00516-z. Epub 2022 Jun 14. Paediatr Drugs. 2022. PMID: 35699915 Review.
Although further data will be useful, dabigatran etexilate is a valuable and convenient treatment option in pediatric VTE. ...Dabigatran etexilate was generally well tolerated; most bleeding events during treatment were minor. ...
Although further data will be useful, dabigatran etexilate is a valuable and convenient treatment option in pediatric VTE. ... …
Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.
Ferro JM, Coutinho JM, Dentali F, Kobayashi A, Alasheev A, Canhão P, Karpov D, Nagel S, Posthuma L, Roriz JM, Caria J, Frässdorf M, Huisman H, Reilly P, Diener HC; RE-SPECT CVT Study Group. Ferro JM, et al. JAMA Neurol. 2019 Dec 1;76(12):1457-1465. doi: 10.1001/jamaneurol.2019.2764. JAMA Neurol. 2019. PMID: 31479105 Free PMC article. Clinical Trial.
Non-vitamin K oral anticoagulants have not been evaluated in randomized controlled trials in CVT. OBJECTIVE: To compare the efficacy and safety of dabigatran etexilate with those of dose-adjusted warfarin in preventing recurrent VTEs in patients who have experienced …
Non-vitamin K oral anticoagulants have not been evaluated in randomized controlled trials in CVT. OBJECTIVE: To compare the efficacy and saf …
Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.
Blair HA, Keating GM. Blair HA, et al. Drugs. 2017 Mar;77(3):331-344. doi: 10.1007/s40265-017-0699-z. Drugs. 2017. PMID: 28185082 Review.
Dabigatran etexilate is a prodrug of dabigatran, a direct inhibitor of thrombin. ...Dabigatran etexilate was also effective and generally well tolerated across various patient subgroups. ...
Dabigatran etexilate is a prodrug of dabigatran, a direct inhibitor of thrombin. ...Dabigatran etexilate …
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.
Halton J, Brandão LR, Luciani M, Bomgaars L, Chalmers E, Mitchell LG, Nurmeev I, Sharathkumar A, Svirin P, Gorbatikov K, Tartakovsky I, Simetzberger M, Huang F, Sun Z, Kreuzer J, Gropper S, Reilly P, Brueckmann M, Albisetti M; DIVERSITY Trial Investigators. Halton J, et al. Lancet Haematol. 2021 Jan;8(1):e22-e33. doi: 10.1016/S2352-3026(20)30368-9. Epub 2020 Dec 5. Lancet Haematol. 2021. PMID: 33290737 Clinical Trial.
BACKGROUND: Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the limitations of standard of care in children with venous thromboembolism. ...Serious adverse events were reported for 18 (20%) of 90 children receiving standard of care and …
BACKGROUND: Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the limitations of standard of care …
Dabigatran etexilate.
Sanford M, Plosker GL. Sanford M, et al. Drugs. 2008;68(12):1699-709. doi: 10.2165/00003495-200868120-00007. Drugs. 2008. PMID: 18681492
Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced platelet aggregation. Dabigatran etexilate pharmacokinetics were linear across …
Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibi …
Dabigatran etexilate: A novel oral direct thrombin inhibitor.
Blommel ML, Blommel AL. Blommel ML, et al. Am J Health Syst Pharm. 2011 Aug 15;68(16):1506-19. doi: 10.2146/ajhp100348. Am J Health Syst Pharm. 2011. PMID: 21817082 Review.
Dabigatran etexilate is a prodrug that is orally absorbed and completely converted to the active form dabigatran by carboxylesterases. Neither the conversion of dabigatran etexilate nor the metabolism of active dabigatran involves the cyt …
Dabigatran etexilate is a prodrug that is orally absorbed and completely converted to the active form dabigatran by car …
Dabigatran etexilate: what do hospitalists need to know?
Zeidan A, Faltas B, Streiff M. Zeidan A, et al. J Hosp Med. 2012 Mar;7(3):262-9. doi: 10.1002/jhm.996. Epub 2011 Nov 29. J Hosp Med. 2012. PMID: 22128108 Review.
Dabigatran etexilate (dabigatran) is a novel, oral, reversible, direct thrombin inhibitor that exhibits several advantages over warfarin for therapeutic anticoagulation. ...The noninferiority design of the clinical trials that evaluated dabigatran and …
Dabigatran etexilate (dabigatran) is a novel, oral, reversible, direct thrombin inhibitor that exhibits several advanta …
Dabigatran etexilate.
Dubois EA, Cohen AF. Dubois EA, et al. Br J Clin Pharmacol. 2010 Jul;70(1):14-5. doi: 10.1111/j.1365-2125.2010.03644.x. Br J Clin Pharmacol. 2010. PMID: 20642542 Free PMC article. No abstract available.
Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence.
Greig SL, McKeage K. Greig SL, et al. Drugs. 2014 Oct;74(15):1785-800. doi: 10.1007/s40265-014-0304-7. Drugs. 2014. PMID: 25270377 Review.
Dabigatran etexilate is an oral prodrug of dabigatran, a selective, reversible, competitive, direct thrombin inhibitor. ...However, in the RE-SONATE trial, dabigatran etexilate was associated with a higher risk of bleeding than placebo. ...
Dabigatran etexilate is an oral prodrug of dabigatran, a selective, reversible, competitive, direct thrombin inhibitor. …
Direct oral anticoagulants: An update.
Franco Moreno AI, Martín Díaz RM, García Navarro MJ. Franco Moreno AI, et al. Med Clin (Barc). 2018 Sep 14;151(5):198-206. doi: 10.1016/j.medcli.2017.11.042. Epub 2017 Dec 30. Med Clin (Barc). 2018. PMID: 29295790 Review. English, Spanish.
Over the past few years, direct oral anticoagulants have emerged, including one direct thrombin inhibitor (dabigatran etexilate) and three factor Xa inhibitors (apixaban, edoxaban and rivaroxaban). In randomised controlled trials comparing direct oral anticoagulants …
Over the past few years, direct oral anticoagulants have emerged, including one direct thrombin inhibitor (dabigatran etexilate …
6,879 results